Ulinastatin can significantly inhibit the expression of the TLR4/MyD88/NF-κB signalling pathway in the intestinal tract, alleviate tissue destruction and inflammatory infiltration in the intestine, and reduce the systemic inflammatory response in mice, thus reducing the mortality of mice and finally exerting a protective effect against sepsis in mice. The gene discussed is NFKB1; the disease is Sepsis.